EUVIMEDEUVIMED entdecken
Crossref

Prevalence and Prognostic Impact of NPM1 Mutation in Childhood Acute Myeloid Leukemia: Experience from a Single Tertiary Cancer Centre in India

Shyam Srinivasan, Mili Aggarwal, Nikhil Patkar, Poorva Gurjar, Chetan Dhamne, Nirmalya Roy Moulik, Akanksha Chichra, Gaurav Chatterjee, Sweta Rajpal, Prashant Tembhare, Dhanalaxmi Shetty, Papagudi G Subramanian und 2 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026

DOI: 10.1016/j.clml.2025.10.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Shyam Srinivasan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India. Electronic address: shyam.sr…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Mutation, Nuclear Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Nucleophosmin (NPM1) mutations are associated with favorable outcomes in adults; however, their prognostic relevance in pediatric acute myeloid leukemia (AML) remains unclear due to their rarity. This single center study from India, investigates the prevalence and prognostic impact of NPM1-mutated childhood AML. METHODS: Patients less than 15 years of age with newly diagnosed AML treated between January 2016 and December 2023 were included. NPM1 and FLT3 mutations were detected via multiplex PCR or next generation sequencing (NGS). Treatment consisted of standard 3 + 7 induction followed by 3 cycles of high-dose cytarabine and 1 year of oral maintenance. FLT3-ITD positive patients also received sorafenib or midostaurin. RESULTS: Of the 552 patients enrolled, 35 (6.3%) had NPM1 mutation. Patients with NPM1- mutations had higher median age (9 vs. 8 years; P = .05) and a greater frequency of FLT3/ITD co-mutations (40% vs. 11%; P < .001). Among the 32 NPM1-mutated patients who underwent NGS, type A (59%) was the most common. While complete remission rates and measurable residual disease negativity were comparable, NPM1-mutated patients demonstrated significantly better 3-year event-free survival (52.1% vs. 26%; P = .001) and overall survival (56.3% vs. 27.8%; P = .004). Although FLT3-ITD status was independently prognostic, it did not influence survival within the NPM1-mutated subgroup. Patients with a VAF < 39% had a better 3-year EFS (73.5% vs. 40.4%; P = .35). CONCLUSIONS: Our study confirms NPM1 mutations independently predict improved survival in pediatric AML, though outcomes remain inferior to those reported from high income countries. Larger studies are needed in pediatric AML due to its rare occurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMutationNuclear ProteinsHumansMaleFemaleChildNucleophosminIndiaPrognosisChild, PreschoolAdolescentPrevalenceInfantTertiary Care Centersfms-Like Tyrosine Kinase 3Antineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

FLT3-ITDNGSNPM1-mutated AMLPediatric AMLPrognosis

Substanzen

NPM1 protein, humanNucleophosminNuclear Proteinsfms-Like Tyrosine Kinase 3

Autor:innen und Institutionen

  • Division of Pediatric Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India. Electronic address: shyam.srinivasan@actrec.gov.in.
  • Division of Pediatric Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India.
  • Department of Hematopathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Department of Cancer Cytogenetics, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.

Zitieren

APA

Srinivasan, S., Aggarwal, M., Patkar, N., Gurjar, P., Dhamne, C., Moulik, N. R., Chichra, A., Chatterjee, G., Rajpal, S., Tembhare, P., Shetty, D., Subramanian, P. G., Narula, G., & Banavali, S. (2026). Prevalence and Prognostic Impact of NPM1 Mutation in Childhood Acute Myeloid Leukemia: Experience from a Single Tertiary Cancer Centre in India. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.10.015

Vancouver

Srinivasan S, Aggarwal M, Patkar N, Gurjar P, Dhamne C, Moulik NR, et al. Prevalence and Prognostic Impact of NPM1 Mutation in Childhood Acute Myeloid Leukemia: Experience from a Single Tertiary Cancer Centre in India. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2025.10.015

BibTeX
@article{Srinivasan2026,
  author = {Srinivasan, Shyam and Aggarwal, Mili and Patkar, Nikhil and Gurjar, Poorva and Dhamne, Chetan and Moulik, Nirmalya Roy and Chichra, Akanksha and Chatterjee, Gaurav and Rajpal, Sweta and Tembhare, Prashant and Shetty, Dhanalaxmi and Subramanian, Papagudi G and Narula, Gaurav and Banavali, Shripad},
  title = {Prevalence and Prognostic Impact of NPM1 Mutation in Childhood Acute Myeloid Leukemia: Experience from a Single Tertiary Cancer Centre in India},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2025.10.015}
}
Kostenlos starten →